1. Home
  2. BAH vs CYTK Comparison

BAH vs CYTK Comparison

Compare BAH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Booz Allen Hamilton Holding Corporation

BAH

Booz Allen Hamilton Holding Corporation

HOLD

Current Price

$79.95

Market Cap

9.6B

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$72.27

Market Cap

10.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAH
CYTK
Founded
1914
1997
Country
United States
United States
Employees
31500
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
10.4B
IPO Year
2010
2004

Fundamental Metrics

Financial Performance
Metric
BAH
CYTK
Price
$79.95
$72.27
Analyst Decision
Hold
Strong Buy
Analyst Count
11
19
Target Price
$97.00
$89.26
AVG Volume (30 Days)
1.8M
2.4M
Earning Date
05-22-2026
05-05-2026
Dividend Yield
3.09%
N/A
EPS Growth
N/A
N/A
EPS
6.90
N/A
Revenue
$11,217,000,000.00
$13,368,000.00
Revenue This Year
N/A
$7.37
Revenue Next Year
$2.14
$310.19
P/E Ratio
$11.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$68.84
$31.99
52 Week High
$120.05
$80.20

Technical Indicators

Market Signals
Indicator
BAH
CYTK
Relative Strength Index (RSI) 52.52 47.56
Support Level $75.89 $59.07
Resistance Level $81.94 $79.66
Average True Range (ATR) 2.92 2.50
MACD 0.41 -1.08
Stochastic Oscillator 59.99 21.01

Price Performance

Historical Comparison
BAH
CYTK

About BAH Booz Allen Hamilton Holding Corporation

Booz Allen Hamilton Holding Corp provides technology solutions in areas such as artificial intelligence, cybersecurity, and related fields. The company serves U.S. federal government agencies, commercial clients, and select international customers. It also provides technologies to evolve defense missions and delivers solutions to warfighters in the digital battlespace.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: